Here we present RNA sequencing (RNA-Seq) of non-small cell lung cancer (NSCLC) and adjacent lung tissue. These samples were acquired from primarily untreated, surgically resected primary tumors. The first analysis published with this data was to determine the metabolic signatures between primary tumors and adjacent lung tissue.The associated clinical trial (<a href="https://clinicaltrials.gov/study/NCT02095808">NCT02095808</a>) includes patients with many kinds of thoracic cancers, including NSCLC and other diseases, such as thymoma and esophageal adenocarcinoma. However, the current dbGaP data is focused on the NSCLCs described in the associated paper.

Metabolic Biomarkers in Thoracic Cancers

Lactate Metabolism in Human Lung Tumors

Metabolic Heterogeneity in Human Lung Tumors

Does Tumor FDG-PET-Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer?